SAB Jan26
Category: Press release
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
medRxiv 2026
Transgene to Participate in Upcoming Investor Meetings
investors 2026
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
resume 2025
Transgene Announces the Success of Its Capital Increase
Results 2025
Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Suspension 2025
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
ESMO AI 2026
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
ESMO Poster
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
ESMO Abstract
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Title SITC